{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:22:38Z","timestamp":1771456958022,"version":"3.50.1"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX09711002-002-009"],"award-info":[{"award-number":["2018ZX09711002-002-009"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703358"],"award-info":[{"award-number":["81703358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejmech.2021.114090","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T20:45:41Z","timestamp":1640724341000},"page":"114090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy"],"prefix":"10.1016","volume":"229","author":[{"given":"Xiu","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minru","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.114090_bib1","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib2","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/acschembio.7b00321","article-title":"Comparison of the deacylase and deacetylase activity of zinc-dependent HDACs","volume":"12","author":"McClure","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.114090_bib6","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1073\/pnas.96.9.4868","article-title":"Three proteins define a class of human histone deacetylases related to yeast Hda1p","volume":"96","author":"Grozinger","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.114090_bib7","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1074\/jbc.M111.273730","article-title":"Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini","volume":"287","author":"Ouyang","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.114090_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/hmg\/ddt402","article-title":"Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance","volume":"23","author":"Cook","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2021.114090_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.molcel.2007.05.033","article-title":"HDAC6 modulates cell motility by altering the acetylation level of cortactin","volume":"27","author":"Zhang","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2021.114090_bib11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2021.114090_bib12","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1073\/pnas.0803749105","article-title":"HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation","volume":"105","author":"Parmigiani","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.114090_bib4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nchembio.2140","article-title":"Structural insights into HDAC6 tubulin deacetylation and its selective inhibition","volume":"12","author":"Miyake","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.114090_bib5","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1021\/acs.biochem.9b00934","article-title":"Structural basis of catalysis and inhibition of HDAC6 CD1, the enigmatic catalytic domain of histone deacetylase 6","volume":"58","author":"Osko","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2021.114090_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105274","article-title":"HDAC6 as privileged target in drug discovery: a perspective","volume":"163","author":"Pulya","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2021.114090_bib13","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.114090_bib14","doi-asserted-by":"crossref","first-page":"127023","DOI":"10.1016\/j.bmcl.2020.127023","article-title":"Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6","volume":"30","author":"Osko","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114090_bib15","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1021\/acs.biochem.8b00367","article-title":"Entropy as a driver of selectivity for inhibitor binding to histone deacetylase 6","volume":"57","author":"Porter","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2021.114090_bib16","doi-asserted-by":"crossref","DOI":"10.4155\/fdd-2020-0023","article-title":"Recent advances in small molecular modulators targeting histone deacetylase 6","volume":"2","author":"Xiao","year":"2020","journal-title":"Future Drug Discov."},{"key":"10.1016\/j.ejmech.2021.114090_bib17","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1021\/acs.jmedchem.8b00258","article-title":"Identification and structure-activity relationship of HDAC6 zinc-finger ubiquitin binding domain inhibitors","volume":"61","author":"Ferreira de Freitas","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib18","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/j.1471-4159.2008.05564.x","article-title":"Histone deacetylase 6 interacts with the microtubule-associated protein tau","volume":"106","author":"Ding","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2021.114090_bib19","article-title":"The role of HDAC6 in cancer","volume":"2011","author":"Aldana-Masangkay","year":"2011","journal-title":"J.\u00a0Biomed. Biotechnol."},{"key":"10.1016\/j.ejmech.2021.114090_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/epi.14.69","article-title":"Histone deacetylase 6 in health and disease","volume":"7","author":"Seidel","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.ejmech.2021.114090_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","article-title":"Histone deacetylase 6 in cancer","volume":"11","author":"Li","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2021.114090_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41419-020-2586-x","article-title":"Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma","volume":"11","author":"Auzmendi-Iriarte","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2021.114090_bib23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jconrel.2020.02.020","article-title":"Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting","volume":"321","author":"Agrawal","year":"2020","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.ejmech.2021.114090_bib24","doi-asserted-by":"crossref","first-page":"C135","DOI":"10.1152\/ajpcell.00136.2018","article-title":"Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke","volume":"316","author":"Yang","year":"2019","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejmech.2021.114090_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","article-title":"Crossing the blood-brain barrier: recent advances in drug delivery to the brain","volume":"31","author":"Patel","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2021.114090_bib26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.biopha.2018.12.133","article-title":"Applications of nanotechnology in drug delivery to the central nervous system","volume":"111","author":"Saeedi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.114090_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2017.05.019","article-title":"Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease","volume":"260","author":"Agrawal","year":"2017","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.ejmech.2021.114090_bib28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2017.09.001","article-title":"Progress in brain targeting drug delivery system by nasal route","volume":"268","author":"Khan","year":"2017","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.ejmech.2021.114090_bib29","doi-asserted-by":"crossref","first-page":"13152","DOI":"10.1021\/acs.jmedchem.1c00910","article-title":"Strategies for structural modification of small molecules to improve blood-brain barrier penetration: a recent perspective","volume":"64","author":"Xiong","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-1326-8-7","article-title":"HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?","volume":"8","author":"Sim\u00f5es-Pires","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejmech.2021.114090_bib31","doi-asserted-by":"crossref","first-page":"19599","DOI":"10.1073\/pnas.0907935106","article-title":"HDAC6 is a target for protection and regeneration following injury in the nervous system","volume":"106","author":"Rivieccio","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.114090_bib34","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1242\/jcs.046813","article-title":"Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6","volume":"122","author":"Zilberman","year":"2009","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ejmech.2021.114090_bib35","article-title":"HDAC6 regulates mitochondrial transport in hippocampal neurons","volume":"5","author":"Chen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.114090_bib36","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nm.2396","article-title":"HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease","volume":"17","author":"d'Ydewalle","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2021.114090_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0006-8993(94)01227-9","article-title":"Early immunohistochemical changes of microtubule based motor proteins in gerbil hippocampus after transient ischemia","volume":"669","author":"Aoki","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2021.114090_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41467-017-00911-y","article-title":"HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients","volume":"8","author":"Guo","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.114090_bib39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/emmm.201201923","article-title":"Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease","volume":"5","author":"Govindarajan","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2021.114090_bib40","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3233\/JAD-140066","article-title":"Tubastatin A\/ACY-1215 improves cognition in Alzheimer's disease transgenic mice","volume":"41","author":"Zhang","year":"2014","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2021.114090_bib41","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2021.114090_bib42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbadis.2011.01.007","article-title":"Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons","volume":"1812","author":"Calkins","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2021.114090_bib43","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1523\/JNEUROSCI.1074-10.2010","article-title":"Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons","volume":"30","author":"Decker","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2021.114090_bib44","doi-asserted-by":"crossref","first-page":"18670","DOI":"10.1073\/pnas.1006586107","article-title":"Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model","volume":"107","author":"Du","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.114090_bib45","article-title":"HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.114090_bib46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.bcp.2012.06.014","article-title":"Development and therapeutic impact of HDAC6-selective inhibitors","volume":"84","author":"Dallavalle","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114090_bib47","first-page":"1","article-title":"The role of histone deacetylase 6 (HDAC6) in neurodegeneration","volume":"2014","author":"Helleputte","year":"2014","journal-title":"Res. Rep. Biol."},{"key":"10.1016\/j.ejmech.2021.114090_bib48","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.114090_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.trci.2015.08.001","article-title":"Pharmacologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein\/presenilin 1 (APP\/PS1) mice","volume":"1","author":"Majid","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.ejmech.2021.114090_bib33","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1021\/acs.jmedchem.8b00151","article-title":"5-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating alzheimer's disease phenotypes","volume":"61","author":"Lee","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/pr.117.014647","article-title":"Neuroimmune axes of the blood-brain barriers and blood-brain interfaces: bases for physiological regulation, disease states, and pharmacological interventions","volume":"70","author":"Erickson","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2021.114090_bib50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0271678X16679420","article-title":"Age-associated physiological and pathological changes at the blood-brain barrier: a review","volume":"37","author":"Erd\u0151","year":"2017","journal-title":"J.\u00a0Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.ejmech.2021.114090_bib51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/138920006775541525","article-title":"The role of blood-brain barrier studies in the pharmaceutical industry","volume":"7","author":"Reichel","year":"2006","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejmech.2021.114090_bib52","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/mp300570z","article-title":"Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states","volume":"10","author":"Deo","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2021.114090_bib53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/neuonc\/nox179","article-title":"Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels","volume":"20","author":"Heffron","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2021.114090_bib54","doi-asserted-by":"crossref","first-page":"10030","DOI":"10.1021\/acs.jmedchem.6b00618","article-title":"Small molecule kinase inhibitors for the treatment of brain cancer","volume":"59","author":"Heffron","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib55","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.114090_bib56","article-title":"Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of \u03b1-tubulin acetylation and FGF-21 up-regulation","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.114090_bib57","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1007\/s11064-019-02882-6","article-title":"Protective effects of ACY-1215 against chemotherapy-related cognitive impairment and brain damage in mice","volume":"44","author":"Wang","year":"2019","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejmech.2021.114090_bib58","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1016\/j.cub.2006.11.036","article-title":"Microtubule modification: acetylation speeds anterograde traffic flow","volume":"17","author":"Bulinski","year":"2007","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2021.114090_bib59","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.cub.2006.09.014","article-title":"Microtubule acetylation promotes kinesin-1 binding and transport","volume":"16","author":"Reed","year":"2006","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2021.114090_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069964","article-title":"SAHA enhances synaptic function and plasticity in\u00a0vitro but has limited brain availability in\u00a0vivo and does not impact cognition","volume":"8","author":"Hanson","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.114090_bib61","series-title":"Pyrimidine Hydroxy Amide Compounds as Protein Deacetylase Inhibitors and Methods of Use Thereof","author":"Duzer","year":"2011"},{"key":"10.1016\/j.ejmech.2021.114090_bib62","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/npp.2013.207","article-title":"Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability","volume":"39","author":"Jochems","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2021.114090_bib63","doi-asserted-by":"crossref","first-page":"15704","DOI":"10.1073\/pnas.1313893110","article-title":"Development of a histone deacetylase 6 inhibitor and its biological effects","volume":"110","author":"Lee","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.114090_bib64","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.brainresbull.2020.06.010","article-title":"Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of \u03b1-phenyl tropolone, HPOB, and sodium valproate","volume":"162","author":"Demyanenko","year":"2020","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2021.114090_bib65","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.1021\/jm400564j","article-title":"Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease","volume":"56","author":"Yu","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib66","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.bbi.2015.06.114","article-title":"An HDAC6 inhibitor for treatment of chemotherapy-induced peripheral numbness and pain in a mouse model","volume":"49","author":"Krukowski","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejmech.2021.114090_bib67","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/j.pain.0000000000000893","article-title":"HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy","volume":"158","author":"Krukowski","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2021.114090_bib68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40478-018-0604-3","article-title":"Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment","volume":"6","author":"Ma","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.ejmech.2021.114090_bib69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/TA.0000000000002119","article-title":"Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock","volume":"86","author":"Nikolian","year":"2019","journal-title":"J.\u00a0Trauma Acute Care Surg."},{"key":"10.1016\/j.ejmech.2021.114090_bib70","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1021\/acscentsci.7b00274","article-title":"HDAC6 brain mapping with [(18)F]Bavarostat enabled by a Ru-mediated deoxyfluorination","volume":"3","author":"Strebl","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2021.114090_bib71","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1021\/acs.jmedchem.8b01013","article-title":"Histone deacetylase 6-selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity","volume":"61","author":"Porter","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib72","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/acsmedchemlett.7b00012","article-title":"Design and synthesis of mercaptoacetamides as potent, selective, and brain permeable histone deacetylase 6 inhibitors","volume":"8","author":"Lv","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114090_bib73","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acsmedchemlett.5b00303","article-title":"Thiol-based potent and selective HDAC6 inhibitors promote tubulin acetylation and T-regulatory cell suppressive function","volume":"6","author":"Segretti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114090_bib74","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1021\/jm070178x","article-title":"Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies","volume":"50","author":"Kozikowski","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib75","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1021\/acschemneuro.8b00600","article-title":"Brain penetrable histone deacetylase 6 inhibitor SW-100 ameliorates memory and learning impairments in a mouse model of fragile X syndrome","volume":"10","author":"Kozikowski","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2021.114090_bib76","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.jmedchem.7b01404","article-title":"Quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in\u00a0vitro and in\u00a0vivo","volume":"61","author":"Lee","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib77","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41419-018-0688-5","article-title":"The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model","volume":"9","author":"Fan","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2021.114090_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110822","article-title":"Phosphodiesterase inhibitors say NO to Alzheimer's disease","volume":"134","author":"Nabavi","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejmech.2021.114090_bib79","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13195-017-0245-y","article-title":"Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression","volume":"9","author":"Hesse","year":"2017","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejmech.2021.114090_bib80","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1021\/acs.jmedchem.6b00908","article-title":"Design, synthesis, and biological evaluation of first-in-class dual acting histone deacetylases (HDACs) and phosphodiesterase 5 (PDE5) inhibitors for the treatment of alzheimer's disease","volume":"59","author":"Rabal","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib81","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejmech.2018.03.005","article-title":"Design, synthesis, biological evaluation and in\u00a0vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease","volume":"150","author":"Rabal","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib82","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1021\/acschemneuro.9b00303","article-title":"Multitarget approach for the treatment of alzheimer's disease: inhibition of phosphodiesterase 9 (PDE9) and histone deacetylases (HDACs) covering diverse selectivity profiles","volume":"10","author":"Rabal","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2021.114090_bib83","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fnagi.2019.00149","article-title":"Taking advantage of the selectivity of histone deacetylases and phosphodiesterase inhibitors to design better therapeutic strategies to treat alzheimer's disease","volume":"11","author":"Cuadrado-Tejedor","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2021.114090_bib84","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1016\/j.bmc.2017.09.028","article-title":"9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment","volume":"25","author":"Makhaeva","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112193","article-title":"Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease","volume":"192","author":"Tseng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113338","article-title":"Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: a preliminary attempt to unravel the enigma of glioblastoma","volume":"217","author":"Nepali","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-4615-2920-0_18","article-title":"Drug transfer across the blood-brain barrier: comparison of in\u00a0vitro and in\u00a0vivo models","volume":"331","author":"Chesn\u00e9","year":"1993","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2021.114090_bib88","series-title":"Aging","first-page":"177","article-title":"Chapter 18 - antioxidant and anti-inflammatory role of melatonin in Alzheimer's neurodegeneration","author":"Rosales-Corral","year":"2014"},{"key":"10.1016\/j.ejmech.2021.114090_bib89","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2174\/1389557515666150522102545","article-title":"Ferulic acid and Alzheimer's disease: promises and pitfalls","volume":"15","author":"Nabavi","year":"2015","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/nyas.14436","article-title":"Therapeutic potential of neurogenesis and melatonin regulation in Alzheimer's disease","volume":"1478","author":"Mihardja","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2021.114090_bib91","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.yexcr.2017.09.015","article-title":"Ferulic acid promotes survival and differentiation of neural stem cells to prevent gentamicin-induced neuronal hearing loss","volume":"360","author":"Gu","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2021.114090_bib92","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1021\/acs.jmedchem.0c01940","article-title":"Melatonin- and ferulic acid-based HDAC6 selective inhibitors exhibit pronounced immunomodulatory effects in\u00a0vitro and neuroprotective effects in a pharmacological alzheimer's disease mouse model","volume":"64","author":"He","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib93","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/acschemneuro.0c00774","article-title":"Preclinical evaluation of an (18)F-labeled SW-100 derivative for PET imaging of histone deacetylase 6 in the brain","volume":"12","author":"Tago","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2021.114090_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113383","article-title":"Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction","volume":"218","author":"Guo","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103365","article-title":"Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitors","volume":"94","author":"Bertran","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.114090_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111643","article-title":"Practical approaches to evaluating and optimizing brain exposure in early drug discovery","volume":"182","author":"Freeman","year":"2019","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:37:41Z","timestamp":1759329461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421009399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":96,"alternative-id":["S0223523421009399"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114090","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114090"}}